Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update

• Published in: Medicina (Kaunas, Lithuania) Lithuania), 2021-01, Vol.57 (1), p.58
• Main Authors: Cicero, Arrigo F G, Fogacci, Federica, Kuwabara, Masanari, Borghi, Claudio
• Format: Article
• Language: English
• Subjects: Acetamides - therapeutic use; Allopurinol - therapeutic use; Benzbromarone - therapeutic use; Chronic Disease; Evidence-Based Medicine; Febuxostat - therapeutic use; Gout Suppressants - therapeutic use; Humans; hyperuricemia; Hyperuricemia - drug therapy; Naphthalenes - therapeutic use; Nitriles - therapeutic use; Phenylacetates - therapeutic use; Polyethylene Glycols - therapeutic use; Probenecid - therapeutic use; Propionates - therapeutic use; Pyridines - therapeutic use; Review; Thioglycolates - therapeutic use; Triazoles - therapeutic use; Urate Oxidase - therapeutic use; uric acid; uric acid-lowering drugs; Uricosuric Agents - therapeutic use; uricosurics; Xanthine Oxidase - antagonists & inhibitors; xanthine oxidase inhibitors
• ISSN: 1648-9144; 1010-660X; 1648-9144
• DOI: 10.3390/medicina57010058

This article aims to critically review the evidence on the available therapeutic strategies for the treatment of hyperuricemia. For this reason, several papers were reviewed. Xanthine oxidase inhibitors are the safest and most effective uric acid lowering drugs for the management of chronic hyperuricemia, while the efficacy of uricosuric agents is strongly modulated by pharmacogenetics. Emergent drugs (lesinurad, peglotidase) were found to be more effective for the acute management of refractory hyperuricemia, but their use is supported by a relatively small number of clinical trials so that further well-designed clinical research is needed to deepen their efficacy and safety profile.